IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

On September 6, 2023 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, reported that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023, at 9:30 a.m. EDT (Press release, IGM Biosciences, SEP 6, 2023, View Source [SID1234634944]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

HOOKIPA Pharma to participate in upcoming investor conferences in September

On September 6, 2023 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported that HOOKIPA’s management team will participate in and present at the following upcoming investor conferences (Press release, Hookipa Pharma, SEP 6, 2023, View Source [SID1234634943]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley Global Healthcare Conference, September 11-13, New York
Fireside Chat: Monday, September 11, 3:35pm ET

H.C. Wainwright Global Investment Conference, September 11-13, New York
Fireside Chat: Tuesday, September 12, 11:30am ET

In addition to the presentations, HOOKIPA will also host one-on-one investor meetings.

Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

On September 6, 2023 Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, reported that the Company will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13 at 12:00 p.m. ET (Press release, Dynavax Technologies, SEP 6, 2023, View Source [SID1234634942]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company’s website at View Source

Corporate presentation

On September 6, 2023 Delcath systems presented its corporate presentation (Presentation, Delcath Systems, SEP 6, 2023, View Source [SID1234634941]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Curis to Present at Upcoming Healthcare Conferences in September

On September 6, 2023 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, reported that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences (Press release, Curis, SEP 6, 2023, View Source [SID1234634940]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The H.C. Wainwright 25th Annual Global Investment Conference being held September 11 – 13, 2023. Presentation details are as follows:

Format: Company Presentation
Date: Tuesday, September 12, 2023
Time: 8:30am ET
The 2023 Cantor Global Healthcare Conference being held September 26 – 28, 2023. Presentation details are as follows:

Format: Panel Presentation
Date: Wednesday, September 27, 2023
Time: 9:10am ET
Webcasts will be available on the Curis website at www.curis.com in the ‘Investors’ section.